TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Acceptability, Feasibility, and Impact of Telelactation Among Rural Mothers
Brief Summary: The investigators will conduct a randomized controlled trial (RCT) to generate data on the impact of direct-to-consumer "telelactation" (virtual breastfeeding support) services. We will explore the feasibility, acceptability, and impact of these services. Postpartum mothers age 18 and older who have initiated breastfeeding will be recruited at a critical access hospital without access to IBCLCs in rural Pennsylvania and randomized into two study arms: 1) outpatient telelactation services via video calls on personal devices or 2) usual care. Data on breastfeeding duration and exclusivity, as well as perceptions and satisfaction with breastfeeding, will be captured via surveys and in-depth interviews and compared across groups.


Options:
A: Arm Label: Telelactation support; Type: EXPERIMENTAL; Interventions: Behavioral: Telelactation services | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telelactation services; Assigned to Arm(s): Telelactation support
B: Intervention Type: BEHAVIORAL; Name: Lactation counseling; Assigned to Arm(s): N/A
C: Arm Label: Arm 1: BCC+PNS+CNS; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition-specific Behaviour change communication (BCC), Dietary Supplement: Nutrient supplement to pregnant women (PNS), Dietary Supplement: Nutrienr supplement to children 6m to 2 years | Arm Label: Arm 2: BCC+PNS; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition-specific Behaviour change communication (BCC), Dietary Supplement: Nutrient supplement to pregnant women (PNS) | Arm Label: Arm 3: BCC+CNS; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition-specific Behaviour change communication (BCC), Dietary Supplement: Nutrienr supplement to children 6m to 2 years | Arm Label: Arm 4: BCC only; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition-specific Behaviour change communication (BCC) | Arm Label: Arm 5: comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nutrition-specific Behaviour change communication (BCC); Assigned to Arm(s): Arm 1: BCC+PNS+CNS, Arm 2: BCC+PNS, Arm 3: BCC+CNS, Arm 4: BCC only | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutrient supplement to pregnant women (PNS); Assigned to Arm(s): Arm 1: BCC+PNS+CNS, Arm 2: BCC+PNS | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutrienr supplement to children 6m to 2 years; Assigned to Arm(s): Arm 1: BCC+PNS+CNS, Arm 3: BCC+CNS
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Breastfeeding related information delivered by WeChat | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-breastfeeding related information delivered by WeChat | Intervention Type: OTHER; Name: Breastfeeding related information delivered by WeChat; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Non-breastfeeding related information delivered by WeChat; Assigned to Arm(s): Control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Integrated Mental Health Care and Vocational Rehabilitation to Individuals on Sick Leave Due to Anxiety and Depression in Denmark (the Danish IBBIS Study): A Multi-center Randomized Controlled Trial
Brief Summary: The purpose of this study is to investigate the efficacy of 1) a stepped mental health care intervention and 2) an integrated mental health care and vocational rehabilitation intervention for people on sick leave because of depression and anxiety in Denmark


Options:
A: Intervention Type: DRUG; Name: DVS-233 SR; Assigned to Arm(s): N/A
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: IBBIS MHC; Type: EXPERIMENTAL; Interventions: Behavioral: IBBIS mental health care and standard vocational rehabilitation | Arm Label: IBBIS integrated MCH and VR; Type: EXPERIMENTAL; Interventions: Other: Integrated mental health care and vocational rehabilitation | Intervention Type: BEHAVIORAL; Name: IBBIS mental health care and standard vocational rehabilitation; Assigned to Arm(s): IBBIS MHC | Intervention Type: OTHER; Name: Integrated mental health care and vocational rehabilitation; Assigned to Arm(s): IBBIS integrated MCH and VR
C: Arm Label: Interpersonal Psychotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interpersonal Psychotherapy, Behavioral: Psychoeducational Group Therapy | Arm Label: Psychoeducational Group Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interpersonal Psychotherapy, Behavioral: Psychoeducational Group Therapy | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Interpersonal Psychotherapy; Assigned to Arm(s): Interpersonal Psychotherapy, Psychoeducational Group Therapy | Intervention Type: BEHAVIORAL; Name: Psychoeducational Group Therapy; Assigned to Arm(s): Interpersonal Psychotherapy, Psychoeducational Group Therapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Low impact exercise | Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low impact exercise; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Brief Summary: This is a Phase 4, randomized, double-blind, placebo-controlled, parallel-group study in subjects aged 12 years and older with CF who are homozygous for the F508del-CFTR mutation. This study is designed to evaluate the effect of LUM/IVA on exercise tolerance in subjects with CF, homozygous for the F508del-CFTR mutation.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium 4-Phenylbutyrate (4PBA), Drug: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein), Drug: Placebo | Intervention Type: DRUG; Name: Sodium 4-Phenylbutyrate (4PBA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA | Intervention Type: DRUG; Name: LUM/IVA; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 10 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 50 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: 50 mg (single dose); Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: 250 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: 250 mg (Fed); Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: 500 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Placebo-Day 1 only; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo-Day 1 only | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): 10 mg, 250 mg, 50 mg, 500 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): 250 mg (Fed), 50 mg (single dose) | Intervention Type: DRUG; Name: Placebo-Day 1 only; Assigned to Arm(s): Placebo-Day 1 only
D: Arm Label: Treatment Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA, Drug: Placebo | Arm Label: Treatment Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA, Drug: Placebo | Intervention Type: DRUG; Name: LUM/IVA; Assigned to Arm(s): Treatment Sequence 1, Treatment Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Treatment Sequence 1, Treatment Sequence 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Brief Summary: This is a Phase 4, randomized, double-blind, placebo-controlled, parallel-group study in subjects aged 12 years and older with CF who are homozygous for the F508del-CFTR mutation. This study is designed to evaluate the effect of LUM/IVA on exercise tolerance in subjects with CF, homozygous for the F508del-CFTR mutation.


Options:
A: Arm Label: Cycling in combination with Flutter® therapy; Type: EXPERIMENTAL; Interventions: Device: Flutter® | Arm Label: Cycling without Flutter® therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: No Flutter® | Intervention Type: DEVICE; Name: Flutter®; Assigned to Arm(s): Cycling in combination with Flutter® therapy | Intervention Type: DEVICE; Name: No Flutter®; Assigned to Arm(s): Cycling without Flutter® therapy
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA | Intervention Type: DRUG; Name: LUM/IVA; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: High Intensity Interval Training; Type: EXPERIMENTAL; Interventions: Other: Educational intervention, Other: Aerobic exercise | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Educational intervention | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Control Group, High Intensity Interval Training | Intervention Type: OTHER; Name: Aerobic exercise; Assigned to Arm(s): High Intensity Interval Training

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Balanced Solution Versus Saline in Intensive Care Study
Brief Summary: A 2x2 factorial randomized study to evaluate the effect of a balanced crystalloid solution compared with 0.9% saline, and of rapid vs. slow infusion on clinical outcomes of critically ill patients


Options:
A: Arm Label: Plasma-Lyte, Slow Infusion; Type: EXPERIMENTAL; Interventions: Drug: Plasma-Lyte, Other: Slow infusion speed | Arm Label: Plasma-Lyte, Fast Infusion; Type: EXPERIMENTAL; Interventions: Drug: Plasma-Lyte, Other: Fast Infusion Speed | Arm Label: Saline 0.9%, Slow Infusion; Type: EXPERIMENTAL; Interventions: Drug: Saline 0.9%, Other: Slow infusion speed | Arm Label: Saline 0.9%, Fast Infusion; Type: EXPERIMENTAL; Interventions: Drug: Saline 0.9%, Other: Fast Infusion Speed | Intervention Type: DRUG; Name: Plasma-Lyte; Assigned to Arm(s): Plasma-Lyte, Fast Infusion, Plasma-Lyte, Slow Infusion | Intervention Type: DRUG; Name: Saline 0.9%; Assigned to Arm(s): Saline 0.9%, Fast Infusion, Saline 0.9%, Slow Infusion | Intervention Type: OTHER; Name: Slow infusion speed; Assigned to Arm(s): Plasma-Lyte, Slow Infusion, Saline 0.9%, Slow Infusion | Intervention Type: OTHER; Name: Fast Infusion Speed; Assigned to Arm(s): Plasma-Lyte, Fast Infusion, Saline 0.9%, Fast Infusion
B: Arm Label: 0.9% sodium chloride; Type: ACTIVE_COMPARATOR; Interventions: Other: 0.9% sodium chloride | Arm Label: Physiologically balanced fluid; Type: ACTIVE_COMPARATOR; Interventions: Other: Physiologically balanced fluid | Intervention Type: OTHER; Name: 0.9% sodium chloride; Assigned to Arm(s): 0.9% sodium chloride | Intervention Type: OTHER; Name: Physiologically balanced fluid; Assigned to Arm(s): Physiologically balanced fluid
C: Arm Label: Lactated ringers solution; Type: EXPERIMENTAL; Interventions: Drug: Lactated Ringer Solution | Arm Label: Normal saline solution; Type: EXPERIMENTAL; Interventions: Drug: Normal Saline 0.9% Infusion Solution Bag | Intervention Type: DRUG; Name: Lactated Ringer Solution; Assigned to Arm(s): Lactated ringers solution | Intervention Type: DRUG; Name: Normal Saline 0.9% Infusion Solution Bag; Assigned to Arm(s): Normal saline solution
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: use of a non balced fluid and of a macromolecular fluid | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: use of balanced crystalloids fluid and macromolecular fluid | Intervention Type: DRUG; Name: use of a non balced fluid and of a macromolecular fluid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: use of balanced crystalloids fluid and macromolecular fluid; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
Brief Summary: In this clinical study the anti-hypertensive response to dietary salt restriction is compared with the anti-hypertensive response to the diuretics hydrochlorothiazide/amiloride in adult patients with chronic kidney disease.


Options:
A: Arm Label: Intervention SUBLIME; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention SUBLIME | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention SUBLIME; Assigned to Arm(s): Intervention SUBLIME
B: Arm Label: Diuretic treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amiloride, Drug: Hydrochlorothiazide | Arm Label: Low-sodium diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Low-sodium diet | Intervention Type: DRUG; Name: Amiloride; Assigned to Arm(s): Diuretic treatment | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Diuretic treatment | Intervention Type: OTHER; Name: Low-sodium diet; Assigned to Arm(s): Low-sodium diet
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Other: Dietary sodium restriction | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Other: Dialysate sodium concentration reduction | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Dietary sodium restriction; Assigned to Arm(s): Group A | Intervention Type: OTHER; Name: Dialysate sodium concentration reduction; Assigned to Arm(s): Group B
D: Arm Label: Sequence: ABBA A=usual care, B=self-care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care management program | Arm Label: Sequence BAAB; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care management program | Arm Label: Sequence AABB; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care management program | Arm Label: Sequence BBAA; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care management program | Intervention Type: BEHAVIORAL; Name: Self-care management program; Assigned to Arm(s): Sequence AABB, Sequence BAAB, Sequence BBAA, Sequence: ABBA A=usual care, B=self-care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
Brief Summary: In this clinical study the anti-hypertensive response to dietary salt restriction is compared with the anti-hypertensive response to the diuretics hydrochlorothiazide/amiloride in adult patients with chronic kidney disease.


Options:
A: Arm Label: Diuretic treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amiloride, Drug: Hydrochlorothiazide | Arm Label: Low-sodium diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Low-sodium diet | Intervention Type: DRUG; Name: Amiloride; Assigned to Arm(s): Diuretic treatment | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Diuretic treatment | Intervention Type: OTHER; Name: Low-sodium diet; Assigned to Arm(s): Low-sodium diet
B: Arm Label: Intensive education of low salt diet; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive education of low salt diet | Arm Label: Conventional diet group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive education of low salt diet; Assigned to Arm(s): Intensive education of low salt diet
C: Arm Label: SCT-based behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SCT-based behavioral intervention | Arm Label: Attention control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: SCT-based behavioral intervention; Assigned to Arm(s): SCT-based behavioral intervention | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): Attention control
D: Arm Label: High risk management; Type: EXPERIMENTAL; Interventions: Behavioral: High-risk patient standardized management package | Arm Label: Salt reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Community based salt reduction program | Arm Label: high risk management and salt reduction; Type: EXPERIMENTAL; Interventions: Behavioral: High-risk patient standardized management package, Behavioral: Community based salt reduction program | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: High-risk patient standardized management package; Assigned to Arm(s): High risk management, high risk management and salt reduction | Intervention Type: BEHAVIORAL; Name: Community based salt reduction program; Assigned to Arm(s): Salt reduction, high risk management and salt reduction

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessing the Risk of Wrong-Patient Errors in an Electronic Health Record That Allows Multiple Records Open
Brief Summary: This study is designed to achieve the following aims:

1. Assess the relationship between the number of records open at the time of placing an order, and the risk of placing an order on the wrong patient.
2. Compare the incidence of wrong-patient orders in a "restricted environment" that limits its providers to only one record open at a time to an "unrestricted environment" where users can open a maximum of four records at once.
3. The results of this study will help inform decisions on how to safely implement EHR systems.
4. The results of this study will inform a larger scale health IT implementation research project evaluating the balance between the wrong-patient error risks and potential efficiency gains of having multiple records open at once, with rigorous research methodologies.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Procedure: New technology - PAML | Intervention Type: PROCEDURE; Name: New technology - PAML; Assigned to Arm(s): Intervention
B: Arm Label: Before collarborative pharmaceutical care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: After collarborative pharmaceutical care; Type: EXPERIMENTAL; Interventions: Other: Collaborative Pharmaceutical Care | Intervention Type: OTHER; Name: Collaborative Pharmaceutical Care; Assigned to Arm(s): After collarborative pharmaceutical care
C: Arm Label: Unrestricted; Type: ACTIVE_COMPARATOR; Interventions: Other: Unrestricted | Arm Label: Restricted; Type: ACTIVE_COMPARATOR; Interventions: Other: Restricted | Intervention Type: OTHER; Name: Unrestricted; Assigned to Arm(s): Unrestricted | Intervention Type: OTHER; Name: Restricted; Assigned to Arm(s): Restricted
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pharmacist obtains home med hx; Type: EXPERIMENTAL; Interventions: Other: Pharmacist obtains admission medication history | Arm Label: Pharm tech obtains home med hx; Type: EXPERIMENTAL; Interventions: Other: Pharmacy technician obtains admission medication history | Intervention Type: OTHER; Name: Pharmacist obtains admission medication history; Assigned to Arm(s): Pharmacist obtains home med hx | Intervention Type: OTHER; Name: Pharmacy technician obtains admission medication history; Assigned to Arm(s): Pharm tech obtains home med hx

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
Brief Summary: The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.


Options:
A: Arm Label: Participants receiving Daprodustat; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat, Drug: Acetylcholine, Drug: Sodium nitroprusside, Drug: L-N-monomethyl arginine acetate (L-NMMA) | Arm Label: Participants receiving Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa, Drug: Acetylcholine, Drug: Sodium nitroprusside, Drug: L-N-monomethyl arginine acetate (L-NMMA) | Intervention Type: DRUG; Name: Daprodustat; Assigned to Arm(s): Participants receiving Daprodustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Participants receiving Darbepoetin alfa | Intervention Type: DRUG; Name: Acetylcholine; Assigned to Arm(s): Participants receiving Daprodustat, Participants receiving Darbepoetin alfa | Intervention Type: DRUG; Name: Sodium nitroprusside; Assigned to Arm(s): Participants receiving Daprodustat, Participants receiving Darbepoetin alfa | Intervention Type: DRUG; Name: L-N-monomethyl arginine acetate (L-NMMA); Assigned to Arm(s): Participants receiving Daprodustat, Participants receiving Darbepoetin alfa
B: Arm Label: rHuEPO or DA to ASP1517; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: rHuEPO or DA to DA; Type: EXPERIMENTAL; Interventions: Drug: DA | Arm Label: Epoetin beta pegol to ASP1517; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Intervention Type: DRUG; Name: roxadustat; Assigned to Arm(s): Epoetin beta pegol to ASP1517, rHuEPO or DA to ASP1517 | Intervention Type: DRUG; Name: DA; Assigned to Arm(s): rHuEPO or DA to DA
C: Arm Label: FG-4592; Type: EXPERIMENTAL; Interventions: Drug: FG-4592 | Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: FG-4592; Assigned to Arm(s): FG-4592 | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin alfa
D: Arm Label: Daprodustat; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat, Drug: Placebo, Drug: Iron Therapy | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa, Drug: Placebo, Drug: Iron Therapy | Intervention Type: DRUG; Name: Daprodustat; Assigned to Arm(s): Daprodustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Daprodustat, Darbepoetin alfa | Intervention Type: DRUG; Name: Iron Therapy; Assigned to Arm(s): Daprodustat, Darbepoetin alfa

Answer: D